Buffalopox Virus Vaccine
As a global leader in vaccine development, Creative Biolabs has always been committed to serving every customer's needs, continuously expanding its team of professional technicians and improving existing technologies and platforms. Now it has a high-end research team, a mature R&D production system. The company is involved in bacteria, viruses and tumor vaccines and so on, especially in the Buffalopox Virus vaccine. With seasoned experts and decades of experience, we are certified to provide you with the most satisfactory service.
Buffalopox Virus
Buffalopox virus is the pathogen of buffalopox, an infectious viral zoonotic disease. Buffalopox virus mainly infects buffalo, cattle, and human, with a mortality rate of up to 80%, which seriously impairs the productivity of animals. The virus can be transmitted by direct or indirect contact through infected contaminants. The disease is regional, mainly prevalent in India and Egypt, in addition, the virus has erupted in Italy, Russia, Bangladesh, Nepal, and Pakistan. Buffalopox virus (BPXV) belongs to the Orthopoxvirus genus, Poxviridae family, and is generally considered to be a close evolutionary strain of VACV and the BP4 strain is generally regarded as a reference strain for this virus.
Fig.1 Typical buffalopox lesions. Lesions over (A) the teats of udder of affected animals and local skin lesions of buffalopox over (B) legs and (C) forehand in milkers and animal handlers. (Bhanuprakash V and Hosamani M, 2012)
Virion Polypeptide
The BPBB strain isolated from infected buffalo, the BPBH strain isolated from the infected human body and the WR strain in VACV were analyzed by SDS-PAGE, and results showed that the three virus strains are compromised with 26, 19 and 29 polypeptides, respectively, among which, 6, 3 and 7 polypeptides are essentially glycoproteins. BPXV-BPBB and BPXV-BPBH have four common polypeptides, and their molecular weights are 42, 26, 18.2, and 14.6 kDa, respectively. Analysis of polypeptide sequences of the virus is a kind of measures to find antigenic relationships between viruses. By analyzing the polypeptides of different isolates of the virus, it is possible to determine not only the phylogenetic relationships between the viruses but also provide guidance for vaccine design and cross-protection among viruses. Creative Biolabs has the world's most advanced instruments and platforms to quickly and accurately identify and analyze the structure and protein of viruses to assist you better understand pathogens and design vaccines.
The Development of the Buffalopox Vaccine
Due to the fact that the major outbreak of buffalopox is popular in India and some buffalo-breeding areas, the endemic feature makes the current research on buffalopox vaccine not widespread. At this stage, there is no buffalopox vaccine available for commercial use in the world. The past effort in preparing buffalopox vaccine including inactivating the virus by formalin and β-propiolactone meanwhile using aluminum hydroxide gel and saponin as adjuvants failed to produce a protective effect on the rabbit model. Subsequently, the attenuated BPXV-BP4 strain adapted from Vero cells and chicken embryo fibroblasts showed efficacy in both rabbit and buffalo models. In addition, the safety and immunogenicity evaluations of the BPXV-Vii96 vaccine candidate prepared in Vero cell to achieve attenuation and the BPXV-BP4 vaccine candidate showed that both vaccine candidates were effective on buffalo calves. Furthermore, the results of seroconversion and challenge tests have also demonstrated that the candidate vaccines are protective. Recent research on buffalopox vaccines are mainly based on live or attenuated buffalopox virus, Maintaining the antigenicity of virions and avoiding their toxicity are two basic principles for designing such vaccines.
Creative Biolabs has unparalleled experience in designing and manufacturing poxvirus vaccines. The company is qualified with the most advanced equipment, a variety of mature cell lines, and a wide range of adjuvants to fully meet your research and development requirements for buffalopox vaccine. We can also provide one-stop services from vaccine design, effectiveness and safety evaluation, formulation optimization to GMP-compliant scale-up production. If you have any needs, please contact us immediately.
Reference
- Bhanuprakash V. (2012). “Animal poxvirus vaccines: a comprehensive review”. Expert Rev Vaccines.11(11):1355-74
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
